Skip to content

Corvus Pharmaceuticals CRVS Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$25.51M
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$32.41M-11.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$114M+256%

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.1B+259%
Enterprise value$1.06B+251%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corvus Pharmaceuticals's investing cash flow?
Corvus Pharmaceuticals (CRVS) reported investing cash flow of -$144.85M in Q1 2026.
How has Corvus Pharmaceuticals's investing cash flow changed year-over-year?
Corvus Pharmaceuticals's investing cash flow decreased by 3513.8% year-over-year, from $4.24M to -$144.85M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.